AMBLor®

About AMLo Biosciences

AMLo Biosciences is a private, pre-revenue diagnostics company developing innovative prognostic tests to better stratify cancer patients by their individual risk of disease progression. Its lead program targets early-stage melanoma, where over 90% of patients are currently over-treated, aiming to redirect resources to high-risk individuals and generate significant healthcare savings. Founded by a team with strong oncology and biotech experience, the company has secured £6.4 million in combined research and equity funding to advance its pipeline, which also includes tests for cutaneous squamous cell carcinoma (cSCC) and oropharyngeal squamous cell carcinoma (OPSCC).

Therapeutic Areas